Dr. Michael Lazar

After 20 years of scrutiny researchers confirm surgery for early prostate cancer may not save lives

Dr. Michael Lazar Director of California HIFU discusses HIFU for Prostate Cancer and the findings of latest study which reveals that radical surgery is not the best way to treat early stage prostate cancer. New treatment options are available and patients need to know.  A 20-year-long study by a national research team including Washington University School of Medicine in St. Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports growing evidence that prostate cancer surgery performed on men in the early stages of the disease offers very few if any benefits. In the cases involved with this study, surgery did not prolong life and often caused serious complications including; infection, urinary incontinence and erectile dysfunction. “As treatments for prostate cancer continue [...]

2017-12-13T13:37:19+00:00July 25th, 2017|

HIFU Patient Returns to the Life He Loves Following Procedure

Over a period of five years, Chris Lockheed’s PSA numbers had been going up. Then, a biopsy revealed that he had two tumors on his prostate. Chris, 68, started doing research into what kind of options for treatment were available to him. When a radiation specialist in Rohnert Park told him about Dr. Michael Lazar and the HIFU procedure, he did more homework. He found that Dr. Lazar had done hundreds of these procedures in Puerto Vallarta, and the treatment was given FDA approval for use in the U.S. in 2015. What is HIFU? HIFU is an FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted [...]

2017-12-13T13:37:19+00:00July 18th, 2017|

Serious Side Effects Noted in Commonly Prescribed Prostate Cancer Drug

Treatment of benign prostatic hyperplasia (BPH) with the commonly prescribed Avodart (Dutsteride) may put men at an increased risk for diabetes, elevated cholesterol levels, non-alcoholic fatty liver disease (NAFLD) and worsening erectile dysfunction. Physicians should be fully aware of these new findings according to the researchers, and to discuss with their patients the potential adverse side effects of Avodart on metabolic and sexual function before prescribing it. The study appears in the journal Hormones Molecular Biology and Clinical Investigations. As men age, their prostate enlarges. This condition often results in urinary retention or other lower urinary tract symptoms, such as reduced urinary flow which results in waking up several times at night to urinate. To help improve symptoms, men are often prescribed an alpha blocker, such [...]

2017-12-13T13:37:20+00:00July 4th, 2017|

Key ingredients to thwart the growth of prostate cancer found in certain foods

When you dine on curry and baked apples, enjoy the fact that you are eating something that could play a role starving -- or even preventing -- cancer. New research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men. Published online this week in Precision Oncology, the new paper uses a novel analytical approach to screen numerous plant-based chemicals instead of testing a single agent as many studies do, discovering specific combinations that shrink prostate cancer tumors. "After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a [...]

2017-12-13T13:37:20+00:00June 13th, 2017|

Hal & Mary: Another Happy HIFU Story

Posted on HIFU Prostate Services 5/27/2017 If you ask Hal Plimpton, he will tell you that he is a semi-retired, international logistics consultant who has owned and operated his own business for many years. If his wife, Mary, happens to hear him say he is “semi” retired, she will laugh and probably roll her eyes. “He was supposed to retire 15 years ago, but he’s still working,” said Mary. However, one thing that Hal and Mary can agree on is that they made a good treatment decision several years ago when Hal was diagnosed with prostate cancer. “I could tell that he felt really good about HIFU (high intensity focused ultrasound). He had confidence in the technology that it was going to work. I was a [...]

2017-12-13T13:37:20+00:00May 31st, 2017|

Doctor’s Own Prostate Cancer Diagnosis Leads to Early Intervention and Positive Results with HIFU

Dr. Michael Lazar of California HIFU shares the story of how friend and fellow surgeon Dr. Robert Pugach underwent HIFU treatment for prostate cancer following an early diagnosis with the disease. Dr. Robert Pugach It’s the news no man wants to hear from a doctor, “… you have prostate cancer.” And when you are a practicing physician who receives this news, all the more room for concern. Dr. Robert Pugach, medical director of Pacific Coast Urology Medical Center was diagnosed with prostate cancer last year and opted to undergo HIFU treatment with urologist and prostate cancer specialist Dr. Michael Lazar of California HIFU earlier this month. What transpired is truly an inspirational account of one man’s journey from diagnosis to cure. Dr. Pugach [...]

2017-12-13T13:37:20+00:00May 23rd, 2017|

New blood test better at predicting prostate cancer risk than PSA

A new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures -- distinguishing cancer from benign conditions, and identifying patients with high-risk disease. By identifying molecular changes in the PSA protein, the findings of this study suggest that once validated, use of IsoPSA may reduce the need for biopsy, and may lower the likelihood of overdetection and overtreatment of nonlethal prostate cancer. A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures -- distinguishing cancer from benign conditions, and identifying patients with high-risk disease. By [...]

2017-12-13T13:37:20+00:00May 16th, 2017|

Study Reveals Quality of Life Concerns Paramount in Prostate Cancer Treatment Options

For many men newly diagnosed with early-stage prostate cancer, concerns about potential quality-of-life issues often guide treatment decisions. A new study led by UNC Lineberger Comprehensive Cancer Center researchers identifies distinct patterns of side effects that patients could use to guide their choices. In the Journal of the American Medical Association, the study examines quality-of-life outcomes for the treatment choices most patients will face. Those choices include active surveillance, radical prostatectomy, external beam radiation treatment, and brachytherapy, a treatment that involves inserting radioactive seeds into the prostate. "Patients diagnosed with early-stage prostate cancer -- and that's the vast majority of patients with this disease -- face many treatment options that are thought to be similarly efficacious," said Ronald C. Chen, MD, MPH, UNC Lineberger member [...]

2017-12-13T13:37:20+00:00March 27th, 2017|

Study reveals genetic connection to aggressive prostate cancer

An international study published in the Journal of the National Cancer Institute has identified a genetic connection to the aggressive form of prostate cancer. The study showed a threefold increase in the risk of aggressive prostate cancer for men with the genetic mutation. The frequency of the gene variants varied from 6 to 14% of the population of men with prostate cancer. Much like the association between BRCA gene mutation and the risk for breast cancer in women changed the approach to treatment/ prevention, the identification of the Kallikrein 6 gene region may change the course of prostate cancer care through a blood test developed by the Lunenfeld-Tanenbaum Research Institute. The study was led by Dr. Alexandre Zlotta, Director of Uro-Oncology at Mount Sinai Hospital, [...]

2017-12-13T13:37:20+00:00March 21st, 2017|

Researchers target cholesterol to stop prostate cancer

Advanced prostate cancer and high blood cholesterol have long been known to be connected, but it has been a chicken-or-egg problem. Now a team led by researchers at the Duke Cancer Institute have identified a cellular process that cancer cells hijack to hoard cholesterol and fuel their growth. Identifying this process could inform the development of better ways to control cholesterol accumulation in tumors, potentially leading to improved survival for prostate cancer patients. The findings are published online this month in the journal Cancer Research. "Prostate cancer cells, as well as some other solid tumors, have been shown to contain higher cholesterol levels than normal cells," said senior author Donald McDonnell, Ph.D., chairman of the Department of Pharmacology and Cancer Biology at Duke. "All cells [...]

2017-03-01T10:01:29+00:00March 1st, 2017|